PE: What policy incentives are created by FDA's ANDA Prioritization Pilot? Botha: Right now, we’re seeing multiple efforts ...

The GCC is becoming a strategic anchor for global venture capital, with Riyadh emerging as a key fundraising hub. Sovereign ...

HHS Secretary Kennedy stated there is insufficient evidence to link Tylenol to autism, conflicting with the Texas lawsuit.

PE: What impact will FDA's ANDA Prioritization Pilot have on efficiency and competitiveness? Botha: Setting up new ...

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli ...

CSL delayed the CSL Seqirus spin-off due to lower-than-expected US vaccination rates, affecting revenue growth and share ...

Novo Nordisk recently confirmed reports about its unsolicited proposal submission to Metsera, aimed at acquiring its early ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F.

The US Health Resources and Services Administration (HRSA) revealed the initial nine drugs to be included in the 340B rebate model. The decision comes after pharma companies filed suit in regard to ...

See how leading teams are achieving measurable impact in just 90 days—without adding validation debt or manual, swivel-chair workflows. Purpose-built, inspection-ready platforms now outpace custom ...

AbbVie revealed it has raised its annual profit forecast for 2025 after sales of its newest immunology drugs Skyrizi and Rinvoq strengthened the company’s Q3 sales number, exceeding expectations set ...

With Most Favored Nation (MFN) and the emergence of the direct-to-consumer (DTC) model and potential tariffs, traditional roles of payers, pharmacy benefit managers, manufacturers, and 340B hospitals ...